Na+/K+ pump Inhibitors
1 drugsAbout Na+/K+ pump
The Na+/K+ pump, or sodium-potassium ATPase, is a plasma membrane protein that actively transports sodium ions out of and potassium ions into animal cells. This maintains electrochemical gradients essential for nerve impulse transmission, muscle contraction, and cell volume.
The Na+/K+ pump is a drug target in the cardiovascular area, but currently lacks genetic evidence linking variations to specific diseases. Further research could reveal connections and support novel therapeutics for diseases involving ion balance.
RUBY-FILL (JUBILANT) is the only FDA-approved drug targeting the Na+/K+ pump, approved in 2016. It is a small molecule used in cardiovascular applications.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Healthy with only 1 trials.
Top Na+/K+ pump Drugs
JUBILANT is the only company with an approved drug targeting the Na+/K+ pump.
Low competition suggests an opportunity for new entrants, but also indicates potential challenges in market development.
Na+/K+ pump Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Na+/K+ pump, using small molecule modality.
The modality landscape indicates a whitespace opportunity for developing novel biologics against this target.
Na+/K+ pump Clinical Trials 1 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Na+/K+ pump Drug Approval Timeline (2016 - 2016)
RUBY-FILL was the first and most recent drug approved in 2016, representing a 1-year approval span.
The lack of recent approvals suggests a saturated market or challenges in developing new therapies for this target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: Moderate (5 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 5 clinical trials targeting Na+/K+ pump.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities